Pre-made Onvatilimab benchmark antibody ( Whole mAb, anti-VSIR therapeutic antibody, Anti-B7-H5/B7H5/C10orf54/DD1alpha/Dies1/GI24/PD-1H/PP2135/SISP1/VISTA Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Onvatilimab biosimilar, Whole mAb, Anti-VSIR Antibody: Anti-B7-H5/B7H5/C10orf54/DD1alpha/Dies1/GI24/PD-1H/PP2135/SISP1/VISTA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Onvatilimab biosimilar, Whole mAb, Anti-VSIR Antibody: Anti-B7-H5/B7H5/C10orf54/DD1alpha/Dies1/GI24/PD-1H/PP2135/SISP1/VISTA therapeutic antibody |
|---|---|
| INN Name | Onvatilimab |
| Target | VSIR |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Janssen Research & Development |
| Conditions Approved | NA |
| Conditions Active | Solid tumours |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | VSIR |
| Package |
